Clinical Trials Browser

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07412405 2026-02-17

ACITAC-001

Phase NA Not yet recruiting

12 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07409428 2026-02-13

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

Phase 3 Not yet recruiting

240 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07398638 2026-02-10

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Phase 1/2 Not yet recruiting

122 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06594939 2026-02-04

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

31 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07310186 2025-12-30

Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

Not yet recruiting

200 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

15 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07197307 2025-09-29

CLEAR

Phase 2 Not yet recruiting

120 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT07168291 2025-09-17

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Phase EARLY_PHASE1 Not yet recruiting

3 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Not yet recruiting

62 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07035379 2025-08-22

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Phase 1/2 Not yet recruiting

66 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06665217 2025-08-14

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

80 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

20 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07012980 2025-06-10

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

Phase 2 Not yet recruiting

38 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06921044 2025-04-10

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

Phase 2 Not yet recruiting

33 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment

NEURO_CAR-T

BAF_FRontier-1

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

ACITAC-001

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

CLEAR

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL